Dacomitinib-Induced Paronychia Associated With PRIDE Syndrome in a Patient With Non-Small Cell Lung Cancer
June 2025
in “
Cureus
”
Studysummary This case study documents a 55-year-old male with advanced NSCLC who experienced toe-predominant paronychia and a papulopustular rash following dacomitinib treatment, with the causality tools indicating a "probable" link, yet the therapy continued successfully without dosage alteration. Our plain-language summary of this paper — not a Tressless recommendation.
This case study describes a 55-year-old male with advanced non-small cell lung cancer (NSCLC) who developed toe-predominant paronychia, a papulopustular rash, and diarrhea after starting dacomitinib, an EGFR inhibitor. The adverse effects were managed symptomatically without discontinuing the drug, highlighting the importance of early recognition and management of such toxicities. Causality was confirmed using multiple assessment tools, indicating a probable link between dacomitinib and the symptoms. This case emphasizes the need for pharmacovigilance and suggests that future research should focus on prophylactic strategies and biomarker discovery to better manage EGFR inhibitor-related toxicities.
